PL2799070T3 - Środek wzmacniający działanie środków przeciwnowotworowych - Google Patents
Środek wzmacniający działanie środków przeciwnowotworowychInfo
- Publication number
- PL2799070T3 PL2799070T3 PL12863476T PL12863476T PL2799070T3 PL 2799070 T3 PL2799070 T3 PL 2799070T3 PL 12863476 T PL12863476 T PL 12863476T PL 12863476 T PL12863476 T PL 12863476T PL 2799070 T3 PL2799070 T3 PL 2799070T3
- Authority
- PL
- Poland
- Prior art keywords
- antitumor agents
- effect potentiator
- potentiator
- effect
- antitumor
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011290125 | 2011-12-28 | ||
| PCT/JP2012/083794 WO2013100014A1 (ja) | 2011-12-28 | 2012-12-27 | 抗腫瘍剤の効果増強剤 |
| EP12863476.3A EP2799070B1 (en) | 2011-12-28 | 2012-12-27 | Effect potentiator for antitumor agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2799070T3 true PL2799070T3 (pl) | 2019-07-31 |
Family
ID=48697493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12863476T PL2799070T3 (pl) | 2011-12-28 | 2012-12-27 | Środek wzmacniający działanie środków przeciwnowotworowych |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140378409A1 (pl) |
| EP (1) | EP2799070B1 (pl) |
| JP (1) | JP5852678B2 (pl) |
| KR (1) | KR101668931B1 (pl) |
| AU (2) | AU2012361581B2 (pl) |
| DK (1) | DK2799070T3 (pl) |
| ES (1) | ES2717898T3 (pl) |
| HU (1) | HUE043991T2 (pl) |
| PL (1) | PL2799070T3 (pl) |
| PT (1) | PT2799070T (pl) |
| RU (1) | RU2589713C2 (pl) |
| TW (1) | TWI594986B (pl) |
| WO (1) | WO2013100014A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105683195B (zh) | 2013-08-22 | 2017-11-10 | 大鹏药品工业株式会社 | 喹啉取代的化合物 |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| WO2016175305A1 (ja) * | 2015-04-30 | 2016-11-03 | 大鵬薬品工業株式会社 | アシルチオウレア化合物のメシル酸塩及びその結晶並びにそれらの製造方法 |
| US10449189B2 (en) | 2015-06-25 | 2019-10-22 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
| EP3508205B1 (en) * | 2016-08-31 | 2022-05-18 | FUJIFILM Corporation | Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit |
| JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| DK3583943T3 (da) | 2017-02-15 | 2024-10-14 | Taiho Pharmaceutical Co Ltd | Farmaceutisk sammensætning |
| MX2020002296A (es) | 2017-09-01 | 2020-09-10 | Taiho Pharmaceutical Co Ltd | Inhibidor selectivo de egfr mutado en el exon 18 y/o el exon 21. |
| KR102584306B1 (ko) | 2017-09-08 | 2023-10-04 | 다이호야쿠힌고교 가부시키가이샤 | 항종양제 및 항종양 효과 증강제 |
| CA3089728C (en) | 2018-01-29 | 2023-01-10 | Fujifilm Corporation | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer |
| AU2019233338B2 (en) | 2018-03-13 | 2022-08-18 | Fujifilm Corporation | Antitumor agent, antitumor effect potentiator and antitumor kit |
| MA53667A (fr) | 2018-09-18 | 2021-07-28 | Taiho Pharmaceutical Co Ltd | Polythérapie associant un composé d'acylthiourée et de l'abiratérone |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN117820332B (zh) * | 2024-03-04 | 2024-05-14 | 烟台大学 | 苯并噻吩-硫脲类化合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60137273D1 (de) * | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| AU2006231646A1 (en) * | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-Met modulators and methods of use |
| WO2009096377A1 (ja) | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 血管阻害物質とタキサンとの併用 |
| JP2011513427A (ja) * | 2008-03-06 | 2011-04-28 | ジェネンテック, インコーポレイテッド | c−met及びEGFRアンタゴニストの併用療法 |
| MX2010011097A (es) * | 2008-04-10 | 2010-11-01 | Taiho Pharmaceutical Co Ltd | Compuesto de aciltiourea o sal del mismo, y uso del mismo. |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| US20110104161A1 (en) * | 2008-05-14 | 2011-05-05 | Burgess Teresa L | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| CN102481299B (zh) * | 2009-02-12 | 2015-02-25 | 艾科尔公司 | 包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物 |
-
2012
- 2012-12-26 TW TW101150217A patent/TWI594986B/zh active
- 2012-12-27 KR KR1020147016594A patent/KR101668931B1/ko active Active
- 2012-12-27 AU AU2012361581A patent/AU2012361581B2/en active Active
- 2012-12-27 ES ES12863476T patent/ES2717898T3/es active Active
- 2012-12-27 JP JP2013551770A patent/JP5852678B2/ja active Active
- 2012-12-27 WO PCT/JP2012/083794 patent/WO2013100014A1/ja not_active Ceased
- 2012-12-27 RU RU2014131058/04A patent/RU2589713C2/ru active
- 2012-12-27 PL PL12863476T patent/PL2799070T3/pl unknown
- 2012-12-27 PT PT12863476T patent/PT2799070T/pt unknown
- 2012-12-27 HU HUE12863476A patent/HUE043991T2/hu unknown
- 2012-12-27 DK DK12863476.3T patent/DK2799070T3/en active
- 2012-12-27 US US14/369,060 patent/US20140378409A1/en not_active Abandoned
- 2012-12-27 EP EP12863476.3A patent/EP2799070B1/en active Active
-
2016
- 2016-06-16 AU AU2016204054A patent/AU2016204054A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2799070A4 (en) | 2015-05-27 |
| RU2589713C2 (ru) | 2016-07-10 |
| DK2799070T3 (en) | 2019-04-23 |
| RU2014131058A (ru) | 2016-02-20 |
| US20140378409A1 (en) | 2014-12-25 |
| JPWO2013100014A1 (ja) | 2015-05-11 |
| AU2012361581B2 (en) | 2016-06-30 |
| TWI594986B (zh) | 2017-08-11 |
| AU2012361581A1 (en) | 2014-07-24 |
| TW201331182A (zh) | 2013-08-01 |
| JP5852678B2 (ja) | 2016-02-03 |
| WO2013100014A1 (ja) | 2013-07-04 |
| KR20140096375A (ko) | 2014-08-05 |
| AU2016204054A1 (en) | 2016-07-07 |
| KR101668931B1 (ko) | 2016-10-24 |
| HUE043991T2 (hu) | 2019-09-30 |
| PT2799070T (pt) | 2019-04-03 |
| EP2799070A1 (en) | 2014-11-05 |
| ES2717898T3 (es) | 2019-06-26 |
| EP2799070B1 (en) | 2019-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2691417T4 (en) | Antistof fc-varianter | |
| PL2799070T3 (pl) | Środek wzmacniający działanie środków przeciwnowotworowych | |
| SG10201601802YA (en) | Dispiropyrrolidine derivatives | |
| GB201109414D0 (en) | Diathermy -ionisation technique | |
| EP2787386A4 (en) | MASK | |
| IL247640A0 (en) | History of heteroaryl piperidine | |
| ZA201403050B (en) | R(+)-n-methyl-propargyl-aminoindan | |
| AP2014007621A0 (en) | 2-Thiopyrimidinones | |
| PL2543408T3 (pl) | Maska do wspomagania oddychania | |
| PT2868660T (pt) | Composto de imidazo-oxazina potenciador de um efeito anti-tumor | |
| EP2691581A4 (en) | joint assembly | |
| ZA201403043B (en) | R(+)-n-formyl-propargyl-aminoindan | |
| SI2766342T1 (sl) | Derivati fenil-gvanidina | |
| ZA201308049B (en) | 3-ureidoisoquinolin-8-yl derivatives | |
| IL216134A0 (en) | Polygraph | |
| AU5171P (en) | Sunparamiho Mandevilla xamabilis | |
| AU5031P (en) | BESYS Beschorneria yuccoides | |
| AU5026P (en) | Goldstrike Agapanthus inapertus | |
| GB201114668D0 (en) | Masking means | |
| GB201114015D0 (en) | Lock-through slit | |
| GB201100370D0 (en) | Concept seven | |
| GB201117537D0 (en) | Citizen-activated-police-response citizen activated-emergency-response | |
| AU337485S (en) | Cabin | |
| ZA201209319B (en) | Cyclopropyl-indole derivatives | |
| GB201114533D0 (en) | Concept 36A |